Why longtime Trump ally and former Republican Gov. Paul LePage is aiming for a political comeback
"I never, ever had any aspirations to go to Washington until now," LePage said this week in his first national interview after launching his bid for the House in Maine's Second Congressional District, which is a top swing seat the GOP aims to flip in the 2026 midterm elections.
The contest will likely be one of the most closely watched House races in the country next year as the Republicans aim to hold their fragile majority in the chamber.
"Donald Trump, I think, is doing what is necessary in addressing the debt this country is facing. And I think that's a big, big thing for me," LePage said as he was interviewed in the Maine city where he was born and raised.
House Republican Campaign Chair Spells Out His Playbook To Hold The Congressional Majority
LePage highlighted, "I have a friend in the White House right now. I know President Trump. I think I can have an audience of President Trump. I know several of his secretaries very well. And so I think this is a good time. It's a good time for me to go help."
Read On The Fox News App
LePage – the brash and blunt politician who won over blue-collar workers struggling with economic woes, which helped the Republican businessman win election and re-election in the blue-leaning state – was one of the first major GOP elected officials to endorse Trump when the president first ran for the White House nearly a decade ago.
"I was Donald Trump before Donald Trump became popular," LePage joked at the time, in a line that's since become famous.
The conservative governor, who grabbed national attention with controversial comments made during his tenure, briefly moved with his wife, Ann, to Florida after finishing his second term in 2019.
"I am done with politics. I have done my eight years. It's time for somebody else," he said at the time.
Congressional Democrats Targeting These House Republicans In 2026 Midterm Battle
But LePage re-established residency in Maine five years ago and challenged his successor as governor, Democratic Gov. Janet Mills, in the 2022 election.
LePage ended up losing his bid for a third term by 13 points to Mills, but he did carry the 2nd Congressional District in that race.
Moderate Democratic Rep. Jared Golden, a U.S. Marine veteran who deployed to the wars in Afghanistan and Iraq, and who often bucks his own party in Congress, has held the seat since first winning it in 2018.
But Golden won re-election by a razor-thin margin last year in the district, which is the second-most rural in the U.S. and the largest east of the Mississippi River.
And Trump, who carried the district in the 2016, 2020 and 2024 presidential elections by nine, seven and 10 points, earned an electoral vote each time, as Maine and Nebraska, are the only two states in the union to allocate their electoral votes partially by congressional district.
Maine's Golden Takes Aim At Fellow Democrats Over Policy
Golden, in a statement after LePage announced his candidacy, said, "I thought Paul was doing his best work in retirement."
But the 42-year-old Golden has yet to announce whether he'll seek re-election next year or instead run for either the state's Senate seat or the open governor's office.
Meanwhile, the Democratic Congressional Campaign Committee (DCCC) spotlighted LePage's tenure as governor.
"Paul LePage's time in office was defined by his obsession with blocking Mainers' ability to receive quality health care, opposing Medicaid expansion at every possible opportunity," DCCC national press secretary Viet Shelton argued in a statement. "At a time when Republicans in Congress are pushing the largest cut to Medicaid in history, Mainers can't afford LePage's crusade to rip health care away from people."
In his Fox News interview, LePage reiterated that the nation's debt is a top motivation for him to return to politics. As of May 8, the national debt was $36,212,886,111,158.26, according to Fox News' National Debt Tracker.
"It's the spending and the debt that this country has, and I'm worried about my grandchildren, great-grandchildren. And I think we have a president now that's really willing to tackle it, and I'm willing to help," he said.
But LePage added that "the other thing that is really big is what's happening in our country with the woke environment. I think I want to be there to help clean that up if we can. Having boys play in girls' sports is really sad."
He also highlighted his Tuesday meeting—part of a three-day swing through the congressional district—with Maine student Cassidy Carlisle, whom he described as "the courageous young woman fighting unfair male competition in girls' sports."
Maine's 2nd Congressional District shares a long border with Canada.
When asked if he'll be spotlighting border security and immigration as major issues in his campaign, Lepage said, "Big time."
But the controversial tariffs the president placed on nations across the globe last month has strained relations with Canada.
"I'm all for the tariffs," LePage said. "The tariffs will fix our international trade and lower taxes."
LePage acknowledged: "Is it going to hurt in the short term? Yeah, it's going to hurt a little bit in the short term, but I think it's necessary."
And he predicted that "the tariffs are going to be a short-term problem. I think they're going to settle out."
LePage spoke with Fox News at Lewiston's Franco Center, a performing arts center and historic site of Franco-American culture located in a former Gothic church built in 1907 for French Canadian immigrants in Maine, which is located alongside the city's historical mills and canals.
The former governor, who survived a troubling and often brutal upbringing, gave Fox News a tour of the many dwellings within blocks of the Franco Center, where he spent his childhood.
The eldest son of 18 children, LePage grew up speaking French in an impoverished home with an alcoholic and abusive father who was a mill worker.
At age 11, he ran away from home after his father beat him and broke his nose. He lived on the streets of Lewiston and often crashed on friends' couches for a couple of years before earning a living shining shoes, washing dishes at a restaurant, and haling boxes for a local truck driver.
"I had a very, very, rough upbringing as a youth. We were in welfare, we were in poverty," he said.
LePage, speaking in the church where he was baptized and sought refuge during his family troubles, told Fox News, "It feels good coming in this building. This was a special building. A couple of nuns and priests were really helpful in my upbringing."
He went on to graduate from high school, and with financial help from friends, attended and graduated from college.
He later enjoyed success as a businessman, including greatly expanding Marden's Surplus and Salvage, a Maine-based discount store chain.
Years later, he ventured into politics, winning election to the Waterville city council and later serving as the city's mayor before winning statewide office in 2010.
The former governor says his rough childhood has influenced his political life in a way that not many other politicians can understand.
And he lamented, "Unfortunately, the mentality in the current society is not to help people get out of poverty, but it's to keep them in poverty."
"I want to help get them out of poverty," he said. "I think there are so many programs that we can institute that will elevate people in poverty, rather than keep them."Original article source: Why longtime Trump ally and former Republican Gov. Paul LePage is aiming for a political comeback
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets
Commercial aviation industry to benefit from access to Leach's trusted product lines through a reliable, scaled and independent distribution partner FDH Electronics & Leach Aerospace OKLAHOMA CITY, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Oklahoma-based FDH Electronics, a unified FDH Aero division focused solely on serving the mil-aero market's electronic component needs, is pleased to announce that its aftermarket division, Stealth Aerospace, has been named as an approved distribution channel by Leach International Corporation to support commercial airline and MRO customers. This strategic partnership builds on the companies' long-standing relationship and reinforces their shared commitment to deliver best-in-class service, product availability and technical support to the commercial aviation aftermarket sector. Alon Glickstein, Vice President at FDH Electronics, commented: 'We are incredibly proud to have established this partnership with Leach International. Their long-standing reputation for high-reliability products fits perfectly with our mission at FDH Electronics — to provide our customers with exceptional service, technical support, and inventory availability that meets their evolving needs.' Leach International, a leading manufacturer of advanced electrical switches, relays, and power distribution components for the aerospace and defense markets, sees this partnership as a key step toward strengthening its presence in the aftermarket segment. Justin Coates, Vice President of Sales & Marketing at Leach International Corporation, added: 'This agreement with FDH Electronics' Stealth Aerospace division ensures that Leach's products will be supported with an incredibly high level of service. Their proven performance in the aerospace aftermarket gives us full confidence that customers will benefit from rapid access to inventory, technical insight, and dedicated aftermarket expertise.' This announcement marks a new chapter in aftermarket excellence and provides the commercial aviation industry with access to Leach's trusted product lines through a specialized and reliable distribution partner. About FDH ElectronicsFDH Electronics is a global one-stop shop with one of the most expansive inventory levels in the industry, built on FDH Aero's industry-leading supply chain solutions. It supplies a variety of interconnect, wire and cable, and electromechanical components for the aerospace, defense, and space markets. FDH Electronics is your go-to resource for value-added connectors, 1553 Data Bus interconnect products, custom harnesses, high-performance aerospace-grade wire and cable, and high-frequency RF connectors. When you need critical interconnect or electromechanical components, you can rely on FDH Electronics to deliver. To search by part number, please visit: Contact:Heather RosenowExecutive Vice President, Marketing & Communicationsmediarelations@ About Leach International CorporationLeach International Corporation has been a leader in aerospace switching and control technology since 1919. Leach designs and manufactures high-reliability relays, contactors, and power distribution systems for aerospace, defense, and industrial applications. Contact:relayed@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Snap Stock Plunged After Earnings. Buy the Dip?
Key Points Sponsored Snaps are showing strong engagement and conversion gains. Subscription revenue from Snapchat+ is growing quickly from a small base. Heavy stock-based compensation and dilution keep valuation concerns high. 10 stocks we like better than Snap › Snap (NYSE: SNAP), the parent company of social media platform Snapchat, took a hard hit following its second‑quarter earnings release earlier this month. Shares tumbled, driven by worries about slowing growth, execution missteps, and a worsening net loss. But dig deeper, and the underlying narrative is more nuanced; there were a lot of positives in the report, too. Revenue and users continue to grow at a robust rate, free cash flow has turned positive year over year, and new ad formats, such as sponsored Snaps, are demonstrating real engagement traction. Given the mix of good and bad in its underlying business and the stock's recent sell-off, it makes sense to check whether the shares have been pushed into oversold territory. Let's look at what changed in the business and what it might mean for investors today. Momentum in key areas Snap reported second-quarter revenue of $1.345 billion, marking a 9% gain from a year earlier. Further, the lifeblood of the company -- user activity -- performed exceptionally well. Daily active users (DAUs) rose 9% to 469 million, while monthly active users (MAUs) climbed 7% to 932 million. Operating cash flow reached $88 million, and free cash flow came in positive at $24 million, a notable reversal from the previous year, when the company burned cash. Still, Snap posted a net loss of $263 million (wider than a net loss of $249 million in the year-ago quarter), and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) slid lower on a year-over-year basis to $41 million, underscoring that profitability remains out of reach. An ad platform glitch -- where auction settings pushed some campaigns to clear at unusually low prices -- weighed on performance early in the quarter. Snap reversed the change mid-period, and management said that advertiser activity is of my favorite data points to support the bull case: On the diversification front, "other revenue" -- primarily from subscriptions like Snapchat+ -- grew 64% year over year, and Snapchat+ subscribers rose roughly 42%, nearing 16 million. One of the quarter's most promising developments was sponsored Snaps -- video ads delivered directly into users' inboxes. Snap co-founder Evan Spiegel said in the company's second-quarter earnings call that after a user opens a sponsored Snap from their chat feed, they "exhibit significantly higher engagement per full-screen ad view, driving a 2x increase in conversion, a 5x increase in click-to-convert ratios and a 2x increase in website dwell times compared to other inventories. That signals a powerful new lever for monetizing deeply engaged the company's fast-growing subscription business, advertising revenue growth trends after the glitch was addressed, and momentum in sponsored Snaps, management guided for continued top-line growth in Q3. Valuation remains a concern Despite a handful of promising trends at Snap, valuation remains troubling. The company has long leaned on equity dilution and stock-based compensation to fund growth. While Q2 did include a $243 million share repurchase (30 million shares), its stock-based compensation burden remains high. Full-year stock-based comp is still pegged north of $1.1 billion, even after recent downward revisions. Keep in mind that we're talking about a company with only a $12 billion market cap. Dilution continues to erode per-share value, even as Snap shows cash generation. So while the sell-off may feel overdone, the stock hasn't quite yet fallen low enough to make it a bargain. Of course, I could be wrong. A potential bull case lies not in near-term profits but in optionality -- whether Snap can scale newer revenue streams, stabilize pricing, and get to a point where it doesn't need to regularly materially dilute shareholders. Overall, Snap trades at a valuation that remains questionable given its history of dilution and heavy reliance on noncash compensation. But the emergence of fast-growing subscription revenue, sponsored Snaps, better cash flow, and an engaged user base make it extremely interesting -- worthy of a high spot on any investor's watchlist. Should you buy stock in Snap right now? Before you buy stock in Snap, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Snap wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Snap Stock Plunged After Earnings. Buy the Dip? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio